RadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212 Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston TX) and AREVA Med (Plano TX) announced today that they have been awarded a collaborative Small Business Innovation...

RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT) Houston, TX, Oct. 20, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston,TX)  is excited to announce the completion of  the Phase I/II  clinical  trial of AminoMedix ™ proprietary formulation used...

RadioMedix successful installations of SmartMedix and All in One (AIO) fully automated radiosynthesizers in USA. Houston, TX, Sept. 12, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce successful installation of SmartMedix ™ (mini AIO) and All in One (AIO) synthesizers powered by Trasis S.A. for...

Viewpoint MT and RadioMedix secured a second SBIR NCI grant for image guided therapy of metastatic melanoma Houston, TX, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Viewpoint Molecular Targeting LLC.(Iowa City, IO) and RadioMedix Inc. (Houston TX) partnership resulted in the second Small Business Innovation...